Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
A phase 3 trial of Moxetumomab pasudotox in Leukaemia, run by MedImmune LLC, completed.
Overview
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia is a phase 3 interventional study registered as NCT01829711 by MedImmune LLC, with 80 participants recorded, started 2013-04-29 and reaching its primary completion in 2017-05-24. Interventions recorded: Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox. Conditions recorded: Leukemia, Hairy Cell.
Linked to the drug Moxetumomab pasudotox because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialMoxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Shares Moxetumomab pasudotox and the tag pipeline.
- TrialTreatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Shares Leukaemia (all types) and the tag pipeline.
- TrialEfficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Shares Leukaemia (all types) and the tag pipeline.
- TrialRasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Shares Leukaemia (all types) and the tag pipeline.
- TrialStudy of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Shares Leukaemia (all types) and the tag pipeline.
- TrialEfficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Shares Leukaemia (all types) and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares AstraZeneca and the tag pipeline.